A major new medical study has revealed that the popular weight-loss drug Semaglutide can significantly reduce the risk of a heart attack or stroke, even if the patient does not lose a significant amount of weight.
The research, published in the prestigious journal The Lancet, suggests that the medication’s benefits extend far beyond just weight reduction and may have a direct positive effect on cardiovascular health.
The trial, led by University College London (UCL), analyzed data from 17,604 individuals aged 45 and older. Half of these participants received weekly injections of Semaglutide (the active ingredient in Wegovy), while the other half received a placebo.
Researchers found that the cardiovascular benefits observed within the first four months of treatment were not dependent on the amount of weight the participants lost. The study did, however, note that a reduction in abdominal (belly) fat was linked to better heart performance.
